138 related articles for article (PubMed ID: 37454705)
1. Vasorin promotes proliferation and migration via STAT3 signaling and acts as a promising therapeutic target of hepatocellular carcinoma.
Wan F; Li H; Huang S; Sun J; Li J; Li Y; Yang L; He M
Cell Signal; 2023 Oct; 110():110809. PubMed ID: 37454705
[TBL] [Abstract][Full Text] [Related]
2. Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-EMSA-SELEX to clinic patient serum.
Li S; Li H; Yang X; Wang W; Huang A; Li J; Qin X; Li F; Lu G; Ding H; Su X; Hou L; Xia W; Shi M; Zhang H; Zhao Q; Dong J; Ge X; Sun L; Bai C; Wang C; Shen X; Fang T; Wang F; Zhang H; Shao N
Oncotarget; 2015 Apr; 6(12):10045-59. PubMed ID: 25826090
[TBL] [Abstract][Full Text] [Related]
3. Long Noncoding RNA HOST2 Promotes Epithelial-Mesenchymal Transition, Proliferation, Invasion and Migration of Hepatocellular Carcinoma Cells by Activating the JAK2-STAT3 Signaling Pathway.
Wu Y; Yuan T; Wang WW; Ge PL; Gao ZQ; Zhang G; Tang Z; Dang XW; Zhao YF; Zhang JY; Jiang GZ
Cell Physiol Biochem; 2018; 51(1):301-314. PubMed ID: 30453302
[TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro effects of microRNA-221 on hepatocellular carcinoma development and progression through the JAK-STAT3 signaling pathway by targeting SOCS3.
Huang S; Zhou D; Li YX; Ming ZY; Li KZ; Wu GB; Chen C; Zhao YN
J Cell Physiol; 2019 Apr; 234(4):3500-3514. PubMed ID: 30370582
[TBL] [Abstract][Full Text] [Related]
5. Exosomal transfer of vasorin expressed in hepatocellular carcinoma cells promotes migration of human umbilical vein endothelial cells.
Huang A; Dong J; Li S; Wang C; Ding H; Li H; Su X; Ge X; Sun L; Bai C; Shen X; Fang T; Li J; Shao N
Int J Biol Sci; 2015; 11(8):961-9. PubMed ID: 26157350
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
7. CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathway.
Zhao Z; Song J; Tang B; Fang S; Zhang D; Zheng L; Wu F; Gao Y; Chen C; Hu X; Weng Q; Yang Y; Tu J; Ji J
J Exp Clin Cancer Res; 2020 Nov; 39(1):259. PubMed ID: 33234142
[TBL] [Abstract][Full Text] [Related]
8. Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1.
Zhang H; Tan YP; Zhao L; Wang L; Fu NJ; Zheng SP; Shen XF
Cell Death Dis; 2020 Jan; 11(1):63. PubMed ID: 31980595
[TBL] [Abstract][Full Text] [Related]
9. Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma.
Mano Y; Aishima S; Fujita N; Tanaka Y; Kubo Y; Motomura T; Taketomi A; Shirabe K; Maehara Y; Oda Y
Pathobiology; 2013; 80(3):146-54. PubMed ID: 23364389
[TBL] [Abstract][Full Text] [Related]
10. Nucleostemin promotes hepatocellular carcinoma by regulating the function of STAT3.
Zhang X; Lv J; Luo H; Liu Z; Xu C; Zhou D; Tang L; Zhang Z; Liu J; Xiao M; Yao Y; Qu L; Lu C
Exp Cell Res; 2020 Feb; 387(1):111748. PubMed ID: 31785228
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA TINCR promotes hepatocellular carcinoma proliferation and invasion via STAT3 signaling by direct interacting with T-cell protein tyrosine phosphatase (TCPTP).
Tang C; Feng W; Bao Y; Du H
Bioengineered; 2021 Dec; 12(1):2119-2131. PubMed ID: 34057016
[TBL] [Abstract][Full Text] [Related]
12. IL-17 Activates the IL-6/STAT3 Signal Pathway in the Proliferation of Hepatitis B Virus-Related Hepatocellular Carcinoma.
Hu Z; Luo D; Wang D; Ma L; Zhao Y; Li L
Cell Physiol Biochem; 2017; 43(6):2379-2390. PubMed ID: 29073625
[TBL] [Abstract][Full Text] [Related]
13. NLRC3 silencing accelerates the invasion of hepatocellular carcinoma cell via IL-6/JAK2/STAT3 pathway activation.
Kang JH; Li MJ; Luan PP; Jiang DK; Chen YW; Xu X; Yu Q; Xu YW; Su Q; Peng WH; Jian WX
Cell Biol Int; 2020 Oct; 44(10):2053-2064. PubMed ID: 32584509
[TBL] [Abstract][Full Text] [Related]
14. MiR-137 suppresses migration and invasion by targeting EZH2-STAT3 signaling in human hepatocellular carcinoma.
Huang B; Huang M; Li Q
Pathol Res Pract; 2018 Dec; 214(12):1980-1986. PubMed ID: 30274685
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of protein disulfide‑isomerase A3 expression inhibits cell proliferation and induces apoptosis through STAT3 signaling in hepatocellular carcinoma.
Kondo R; Ishino K; Wada R; Takata H; Peng WX; Kudo M; Kure S; Kaneya Y; Taniai N; Yoshida H; Naito Z
Int J Oncol; 2019 Apr; 54(4):1409-1421. PubMed ID: 30720090
[TBL] [Abstract][Full Text] [Related]
16. miR-383 inhibits cell growth and promotes cell apoptosis in hepatocellular carcinoma by targeting IL-17 via STAT3 signaling pathway.
Wang J; Lu L; Luo Z; Li W; Lu Y; Tang Q; Pu J
Biomed Pharmacother; 2019 Dec; 120():109551. PubMed ID: 31648164
[TBL] [Abstract][Full Text] [Related]
17. EFTUD2 maintains the survival of tumor cells and promotes hepatocellular carcinoma progression via the activation of STAT3.
Tu M; He L; You Y; Li J; Yao N; Qu C; Huang W; Xu L; Luo R; Hong J
Cell Death Dis; 2020 Oct; 11(10):830. PubMed ID: 33024090
[TBL] [Abstract][Full Text] [Related]
18. Rheum palmatum extract exerts anti-hepatocellular carcinoma effects by inhibiting signal transducer and activator of transcription 3 signaling.
Tan ZB; Fan HJ; Wu YT; Xie LP; Bi YM; Xu HL; Chen HM; Li J; Liu B; Zhou YC
J Ethnopharmacol; 2019 Mar; 232():62-72. PubMed ID: 30553869
[TBL] [Abstract][Full Text] [Related]
19. PHD2 acts as an oncogene through activation of Ras/Raf/MEK/ERK and JAK1/STAT3 pathways in human hepatocellular carcinoma cells.
Guo J; Lan Z
Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):37-45. PubMed ID: 31852247
[No Abstract] [Full Text] [Related]
20. NCAPG2 overexpression promotes hepatocellular carcinoma proliferation and metastasis through activating the STAT3 and NF-κB/miR-188-3p pathways.
Meng F; Zhang S; Song R; Liu Y; Wang J; Liang Y; Wang J; Han J; Song X; Lu Z; Yang G; Pan S; Li X; Liu Y; Zhou F; Wang Y; Cui Y; Zhang B; Ma K; Zhang C; Sun Y; Xin M; Liu L
EBioMedicine; 2019 Jun; 44():237-249. PubMed ID: 31176678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
